CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
Cho-Chung
Y S
YS
Cellular Biochemistry Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892-1750, USA.
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001665:Binding Sites; D016384:Consensus Sequence; D000242:Cyclic AMP / Q000502:physiology; D015195:Drug Design; D004742:Enhancer Elements, Genetic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D015316:Genetic Therapy; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009690:Nucleic Acid Conformation; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011485:Protein Binding; D012045:Regulatory Sequences, Nucleic Acid; D015290:Second Messenger Systems / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects*; D013329:Structure-Activity Relationship; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D014157:Transcription Factors; D000242:Cyclic AMP